Memo Therapeutics
Executives
View the org chart displaying its 14 main executives
Most searched biographies at Memo Therapeutics
- Erik Van Den Berg, Chief Executive Officer
- Elias Papatheodorou, Independent Chairman of the Board
- Christian Schneider, Director
Popular executive movements at Memo Therapeutics
- Maartje Verschuur has joined the company as Vice President, Chemistry, Manufacturing, and Controls and Supply Chain Management (posted on February 6 2024).
- Kristie Clemmer has joined the company as Vice President, Clinical Operations (posted on February 6 2024).
- Erik Van Den Berg has joined the company as Chief Executive Officer (posted on November 17 2023).
Click here to view some more movements at Memo Therapeutics
Create your alert
to follow the executive moves at Memo Therapeutics.
Biotechnology
Memo Therapeutics has 2,282 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Memo Therapeutics
- Memo Therapeutics AG Strengthens Management Team - Memo Therapeutics AG
- Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer - Memo Therapeutics AG
- Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- MEMO THERAPEUTICS AG PRESENTED AT SWISS NORDIC BIO 2017 IN ZURICH - Memo Therapeutics AG
- Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Memo Therapeutics AG
- Memo Therapeutics AG initiates phase 1 clinical study of MTX-005 against BK virus infection - Memo Therapeutics AG
- Memo Therapeutics AG initiates phase 1 clinical study of COVAB 36 against SARS-CoV-2 - Memo Therapeutics AG
- View more press releases Close
Social media about Memo Therapeutics
- Memo Therapeutics on Wikipedia, Google News & Yahoo Finance
- Memo Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Erik Van Den Berg 
Call Memo Therapeutics at +41 44...
